Home > others & > Eltrombopag Olamine

Eltrombopag Olamine

艾曲波帕乙醇胺,SB-497115-GR,SB497115,SB 497115,SB-497115,

Eltrombopag是口服活性的促血小板生成素受体激动剂。

目录号
EY0732
EY0732
EY0732
EY0732
纯度
99.23%
99.23%
99.23%
99.23%
规格
1 mg
5 mg
10 mg
50 mg
原价
220
466
770
2100
售价
220
466
770
2100
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Erickson-Miller CL, et al. Stem Cells, 2009, 27(2), 424-430.
    [2] McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36.
    [3] Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

    分子式
    C29H36N6O6    		 分子量
    564.63    		 CAS号
    496775-62-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    90 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01550185 Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia Drug: eltrombopag olamine|Procedure: standard follow-up care Roswell Park Cancer Institute|National Cancer Institute (NCI)|GlaxoSmithKline Phase 1 2012-05-01 2016-04-04
    NCT02071901 Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia Drug: eltrombopag olamine Case Comprehensive Cancer Center|National Cancer Institute (NCI) Phase 2 2014-08-01 2016-10-04
    NCT01772420 Adult Myelodysplastic Syndrome|Anemia|Chronic Myelomonocytic Leukemia Drug: Eltrombopag Olamine|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI) Phase 2 2012-10-01 2016-01-14
    NCT01098487 Purpura, Thrombocytopaenic, Idiopathic Drug: Eltrombopag olamine GlaxoSmithKline Phase 4 2010-05-01 2015-02-26
    NCT00351468 Purpura, Thrombocytopaenic, Idiopathic Drug: eltrombopag olamine (SB-497115-GR) Novartis Phase 3 2006-06-01 2016-03-22
    NCT01147809 Thrombocytopaenia Drug: Eltrombopag olamine|Other: Placebo GlaxoSmithKline Phase 2 2010-06-01 2016-03-17
    NCT01610180 Purpura, Thrombocytopenic, Idiopathic|Autoimmune Thrombocytopenic Purpura|Autoimmune Thrombocytopenia|Chronic Lymphocytic Leukemia|Non Hodgkin's Lymphoma Drug: Eltrombopag Olamine Fondazione Progetto Ematologia Phase 2 2012-06-01 2012-09-25
    NCT00643929 Purpura, Thrombocytopaenic, Idiopathic Drug: Eltrombopag GlaxoSmithKline 2007-02-01 2017-03-21
    NCT02201290 Purpura, Thrombocytopenic, Idiopathic Drug: Eltrombopag Tablets|Drug: Eltrombopag PfOS Novartis Pharmaceuticals|Novartis Phase 3 2013-06-01 2016-08-08
    NCT00424177 Purpura, Thrombocytopaenic, Idiopathic Drug: eltrombopag GlaxoSmithKline Phase 2 2007-03-01 2013-07-25
    NCT00370331 Purpura, Thrombocytopenic, Idiopathic Drug: eltrombopag|Drug: Placebo GlaxoSmithKline Phase 3 2006-11-01 2012-11-21
    NCT00903422 Myelodysplastic Syndrome Drug: eltrombopag olamine|Other: Placebo GlaxoSmithKline Phase 1 2009-05-01 2015-02-23
    NCT02158936 Thrombocytopaenia Drug: Eltrombopag|Drug: Azacitidine|Drug: Placebo Novartis Pharmaceuticals|Novartis Phase 3 2010-02-01 2017-02-07
    NCT01830660 Healthy Drug: Hetrombopag Olamine Tablets|Drug: placebo Jiangsu HengRui Medicine Co., Ltd. Phase 1 2012-04-01 2015-04-03
    NCT01957176 Thrombocytopaenia Drug: ELT Novartis Pharmaceuticals|Novartis Phase 4 2013-10-01 2017-02-01

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：